Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (DE:RGN)
FRANKFURT:RGN
Holding DE:RGN?
Track your performance easily
RGN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€104.60 - €192.00
Previous Close€131.85
Volume0.00
Average Volume (3M)52.00
Market Cap
€7.35B
Enterprise Value€7.29B
Total Cash (Recent Filing)$809.15M
Total Debt (Recent Filing)$742.85M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Oct 29, 2024EPS Estimate
€0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding56,006,498
10 Day Avg. Volume0
30 Day Avg. Volume52
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)13.23
Price to Sales (P/S)13.64
Price to Cash Flow (P/CF)48.70
P/FCF Ratio54.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.11
Enterprise Value/Gross Profit25.61
Enterprise Value/Ebitda123.58
Forecast
1Y Price Target
€175.21Price Target Upside34.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Repligen News
Bulls Say, Bears Say
Bulls Say
AcquisitionRepligen announced the acquisition of Tantti which strengthens the Proteins and Chromatography Franchise alongside new product launches.
GrowthOrders growing +5% QoQ and the company's return to double-digit base business revenue growth.
LeadershipCEO-elect Loeillot confirmed that he expects double digit growth for Repligen over the next decade and outlined his top 3 priorities.
Bears Say
AcquisitionShareholder dilution is a concern with the acquisition offer.
Bioprocessing RecoveryConcerns about bioprocessing recovery, especially following recent BIO conference where participants signaled a slower-than-hoped recovery in bioprocessing.
RevenueA material portion of the company's revenue would shift to services, which the market assigns a lower multiple.
---
RGN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was €104.60 and its highest was €192.00 in the past 12 months.
What is Repligen Corp’s market cap?
Currently, no data Available
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Oct 29, 2024 which is in 58 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Jul 30, 2024. The company reported €0.294 earnings per share for the quarter, beating the consensus estimate of €0.291 by €0.004.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is €0.3.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,006,496 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of €0.294 in its last earnings report, beating expectations of €0.291. Following the earnings report the stock price went down -1.944%.
Which hedge fund is a major shareholder of Repligen Corp?
Among the largest hedge funds holding Repligen Corp’s share is Sands Capital Management LLC. It holds Repligen Corp’s shares valued at 179M.
---
Repligen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€175.21 (34.98% Upside)
€175.21 (34.98% Upside)
Blogger Sentiment
Neutral
DE:RGN Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.99%
12-Months-Change
Fundamentals
Return on Equity
-0.10%
Trailing 12-Months
Asset Growth
12.28%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
---
RGN Earnings Call
Q2 2024
0:00 / 0:00
---
RGN Revenue Breakdown
99.94% Product revenue
0.06% Royalty and other income
---
RGN Stock 12 Month Forecast
Average Price Target
€175.21
▲(34.98% Upside)
Technical Analysis
Repligen
―
Atara Biotherapeutics
―
Amgen
―
BioMarin Pharmaceutical
―
Fate Therapeutics
―
Best Analysts Covering RGN
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+24.38%
reiterated a buy rating 16 days ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +24.38% per trade.
---